Marché de la viscosupplémentation en Amérique du Nord – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et perspectives du marché de la viscosupplémentation en Amérique du Nord

Le marché nord-américain de la viscosupplémentation devrait croître au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 8,7 % au cours de la période de prévision de 2022 à 2029. Les avancées technologiques dans les traitements de viscosupplémentation en Amérique du Nord et l'augmentation dans le secteur de la santé sont un autre facteur qui stimule la croissance du marché nord-américain de la viscosupplémentation au cours de la période de prévision.

Cependant, le coût élevé associé aux traitements et aux effets secondaires tels que l'injection temporaire, la douleur au site, le gonflement, la chaleur et la perte de rougeur freineront la croissance du marché. L'adoption d'alliances stratégiques telles que les partenariats et les acquisitions par des acteurs clés du marché constitue une opportunité pour la croissance du marché nord-américain de la viscosupplémentation.

Définition du marché

The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.

Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market. 

Market Dynamics                                        

Drivers

• Rising geriatric population

With this increasing age comes a reciprocal increase in the elderly patients admitted to the hospitals due to fatal traumatic injuries. The rising prevalence of knee osteoarthritis diseases leads to increasing demand for diagnosis and treatment. With the growing population, the pressure on the healthcare system is rising. The increasing need for the proper treatment proportionally surges the demand for care, services, and technologies for the prevention and treatment of knee osteoarthritis conditions such as sarcopenia, osteoporosis, osteopenia, and other complications. The elderly population is more prone to these conditions leading to fragile bones and joints. In such patients, viscosupplementation is used in the procedure to provide them with immediate and efficient benefits associated with their bodies.

With this increasing age and rising prevalence of osteoarthritis, the demand for early diagnosis of the diseases is also increasing. Therefore, the demand for viscosupplementation is rising for the treatment in the healthcare system across the globe.

• Increasing risk of osteoporosis and osteoarthritis

Osteoporosis is a disease of bone that progresses due to less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength. It is more observed in women as compared to men. The post-menstrual women often get bone fractures due to osteoporosis as the disease is silent and typically shows no symptoms. Mostly elderly people are more prone to osteoporosis. Osteoarthritis is a joint disease or an inflammation of the joints and surrounding tissues. The mobility of a person is affected when such conditions occur.

The silent diseases such as osteoporosis and osteoarthritis show no symptoms and weaken the person's bone, leading to major fatalities such as spine malformation, fracture, sudden fall, or breakage of bone, among others. Thus, the increased risks of these conditions directly enhance the demand for viscosupplementation required to treat the malformations due to such conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive the growth of the North America viscosupplementation market.

Restraint

• Lack of technical expertise

Finding, attracting, and hiring talent is also the first step in building a professional bench of engineers and technicians. Even in the best of circumstances, this procedure can be challenging. Manufacturing existing workforce is rapidly aging and retiring. In the medical industry, there is a scarcity of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and undergraduate/post-graduate skills (engineers) remains strong in manufacturing, the number of people with the necessary skills is approaching a trickle. Only trained professionals should perform viscosupplementation, but this number is much less across the globe as these procedures are complex.

However, putting together a good additive manufacturing (AM) workforce entails more than just finding and recruiting qualified candidates. Employees must be qualified to remain current and maintain required skills as technology shift and grow. Even with their STEM-focused education, newly minted engineers would certainly need on-the-job training in AM techniques, which is one of the major challenges of recruiting and hiring them. Indeed, many undergraduate engineering programs provide little in the way of AM-specific education, and as a result, many graduates can lack the AM skills that employers seek.

Thus, the lack of technical expertise may act as a restraint for the market's growth.

Opportunity

• Safety and effectiveness of intra-articular hyaluronic acid (IAHA)

There are several types of hyaluronic acid injections, also called viscosupplementation, which are used for knee osteoarthritis. They are made from either rooster or chicken combs or are derived from bacteria and are injected directly into the joint. Intra-articular hyaluronic acid is a US Food and Drug Administration-approved treatment for knee osteoarthritis (OA). Intra-articular hyaluronic acid (IAHA) injection presents an alternative local treatment option providing symptomatic benefit without the systemic AEs associated with IA corticosteroids. Numerous RCTs and meta-analyses have sought to assess the efficacy and safety of IAHA, with mixed results and conclusions. IAHA is demonstrated to have a positive effect on pain and joint function. There is also mounting data showing that multiple courses of IAHA can impact long-term outcomes, including a reduction in concomitant analgesia use and a delay in the need for total knee replacement surgery.

Challenge

• Stringent government policies for THE USE OF viscosupplementation

The commercialization of viscosupplementation across the globe by various key market players is facilitated by compliance with the regulatory frameworks established by many countries across the globe. The pre-market approval of various medical devices varies from one country to another. The U.S. Food, Drug, and Cosmetic Act ("FD&C Act") classify medical devices in the U.S. The European Union (EU) regulates medical devices in Europe. However, the rapid development of privacy policies and regulations are being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia.

The viscosupplementation is regulated by a structure of laws, rules, and regulations that are extensive and complex to safeguard them from use in any potential harmful treatment.

The viscosupplementation act as a replacement for the damaged, injured, or infected body parts in cases of osteoarthritis conditions or sports accidents among patients, along with maintaining the patient's demand for good body movement. However, any misguidance will affect the patient's safety and body structure.

Therefore, the stringent rules & regulations for the use of viscosupplementation may act as a challenge to the growth of the market.

Post-COVID-19 Impact on North America Viscosupplementation Market

COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to impact the North America viscosupplementation market greatly.

North America Viscosupplementation Market Scope and Market Size

North America viscosupplementation market is segmented on the basis of source, age group, molecular weight, injection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.

BY SOURCE

• ANIMAL ORIGIN
• NON-ANIMAL ORIGIN

On the basis of source, the viscosupplementation market is segmented into the animal origin and non-animal origin.

BY MOLECULAR WEIGHT

• HIGH MOLECULAR WEIGHT
• LOW MOLECULAR WEIGHT
• INTERMEDIATE MOLECULAR WEIGHT

On the basis of molecular weight, the viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight.

BY INJECTION

• SINGLE INJECTION
• THREE INJECTION
• FIVE INJECTION

On the basis of injection, the viscosupplementation market is segmented into single injection, three injections, and five injections.

BY AGE GROUP

• ADULTS
• GERIATRICS

On the basis of age group, the viscosupplementation market is segmented into geriatric and adults.

END-USER

• HOSPITALS
• ORTHOPEDIC CLINIC
• HOME HEALTHCARE
• OTHERS

On the basis of end-user, the viscosupplementation market is segmented into hospital, orthopedic clinics, ambulatory care centers, and others.

BY DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES

On the basis of distribution channel, the viscosupplementation market is segmented into direct tender and retail sales.

Viscosupplementation Market Country Level Analysis

The viscosupplementation market is analyzed, and market size information is provided by source, age group, molecular weight, injection, end user, and distribution channel.

The countries covered in the North America viscosupplementation market report are U.S., Canada, Mexico, Panama, Jamaica and the Dominican Republic.

In 2022, the U.S. is dominating due to the growing preference for alternative corticosteroids for joint pain management treatment options. The U.S is expected to grow due to the rise in technological advancement in drug treatments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

Le marché nord-américain de la viscosupplémentation vous fournit également une analyse de marché détaillée de la croissance de chaque pays dans le secteur de la santé. De plus, il fournit des informations détaillées sur les services et traitements de santé, l'impact des scénarios réglementaires et les paramètres de tendance concernant le marché nord-américain de la viscosupplémentation.

Analyse du paysage concurrentiel et des parts de marché de la viscosupplémentation en Amérique du Nord

Le paysage concurrentiel du marché de la viscosupplémentation en Amérique du Nord fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers les traitements de viscosupplémentation.

Les principales sociétés actives sur le marché de la viscosupplémentation sont Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici SPA, Ferring BV, sanofi-aventis US LLC, Zimmer Biomet, OrthogenRx, Inc. (une filiale d'AVNS), APTISSEN. , Johnson & Johnson Services, Inc., LG Chem., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (une filiale de Landec Corporation), VIRCHOW BIOTECH, Zuventus HealthCare Ltd . (une filiale d'Emcure Pharmaceuticals), entre autres.

Les alliances stratégiques telles que les fusions, les acquisitions et les accords entre les principaux acteurs du marché devraient également accélérer la croissance des traitements de viscosupplémentation.

Par exemple,

• En mai 2022, Fidia Farmaceutici SpA exploite le pouvoir régénérant de l'acide hyaluronique avec son portefeuille innovant lancé en Espagne

Fidia Farmaceutici SpA a présenté son portefeuille de soins esthétiques avec un symposium scientifique sur sa technologie innovante ACP (Auto-Crosslinked Polymer) lors du 20e Congrès mondial de médecine esthétique et anti-âge 2022 (AMWC) à Monte-Carlo. La société a lancé son portefeuille complet Hyal System et Hy-Tissue en Espagne. Cela a permis à l'entreprise de présenter ses recherches sur l'acide hyaluronique

• En juin 2022, Johnson & Johnson a annoncé de nouvelles données issues d'études de phase 3 démontrant que les patients traités avec le médicament ont obtenu une efficacité constante à long terme sur deux ans dans les domaines de l'arthrite psoriasique active (AP) - y compris les critères d'évaluation des articulations, de la peau, de l'enthésite, de la dactylite, de la douleur rachidienne et de la gravité de la maladie - indépendamment des caractéristiques de base. Cela a aidé l'entreprise à mettre en valeur ses progrès
• En novembre 2021, LG Chem a lancé le développement clinique d'un nouveau traitement de nouvelle génération contre l'arthrose. LG Chem a annoncé que la société avait reçu l'approbation du ministère coréen de la sécurité alimentaire et pharmaceutique pour les essais cliniques de phase 1b/2 sur la base des résultats précliniques positifs de LG00034053, un nouveau candidat médicament pour le traitement de l'arthrose. LG Chem prévoit d'accélérer le développement de nouveaux médicaments en concevant des essais cliniques reliant les phases 1 et 2.

Cela a aidé l'entreprise à se lancer dans de nouveaux médicaments pour le traitement de l'arthrose

• En novembre 2020, Viatris Inc. a lancé avec succès une fusion entre Mylan NV et l'entreprise Upjohn de Pfizer. En combinant ces deux sociétés complémentaires, Viatris dispose de l'expertise scientifique, de fabrication et de distribution ainsi que de capacités réglementaires, médicales et commerciales éprouvées en Amérique du Nord pour fournir des médicaments de haute qualité aux patients dans plus de 165 pays et territoires. Cela a aidé l'entreprise à développer ses activités.

La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché renforcent l'empreinte de l'entreprise sur le marché nord-américain de la viscosupplémentation, ce qui profite également à la croissance des bénéfices de l'organisation.

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des parts de marché des entreprises, les normes de mesure, l'Amérique du Nord par rapport aux régions et l'analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.

SKU-68854